- Home
- DHF vs FENC Comparison
DHF vs FENC Comparison
Compare DHF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$6.72
Company Overview
Basic Information| Metric | DHF | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.0M | 266.4M |
| IPO Year | 1998 | 2010 |
Fundamental Metrics
Financial Performance| Metric | DHF | FENC |
|---|---|---|
| Price | $2.43 | $6.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | ★ 196.4K | 140.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.33 | $5.65 |
| 52 Week High | $2.63 | $9.92 |
Technical Indicators
Market Signals| Indicator | DHF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 50.26 |
| Support Level | N/A | $5.65 |
| Resistance Level | $2.44 | $8.09 |
| Average True Range (ATR) | 0.02 | 0.36 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 57.89 | 74.23 |
Price Performance
Historical Comparison DHF
FENC
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.